No Data
Hong Kong stocks are active | CRO concepts generally rise, medical insurance negotiations support innovative drugs, and under the environment of interest rate cuts, global biomedical financing will rebound.
The concept of CRO is generally on the rise. As of the time of publication, Asymchem Laboratories (06821) rose by 4.95%, to HKD 59.4; Tigermed (03347) rose by 4.94%, to HKD 38.25; Wuxi Apptec (02359) rose by 3.88%, to HKD 53.5.
Hong Kong stock concept tracking | The end of medical insurance negotiations is very encouraging for innovative drugs to be included in medical insurance at reasonable prices (with concept stocks)
The on-site negotiation and bidding stages for the adjustment of the national medical insurance pharmaceutical catalog in 2024 officially ended recently.
Historically the most 'competitive'? The Tenth Batch of National Procurement Pharmaceutical Catalog Is Officially Announced with one type having up to 31 companies competing.
①This afternoon, the National Pharmaceutical Joint Procurement Office officially announced the tenth batch of nationally purchased pharmaceutical catalog, with a total of 263 specifications and 62 varieties; ②Several industry insiders have stated that the tenth batch of national procurement will be the largest and most competitive national procurement in history.
zheshang: Continuous realization of technological innovation upgrade driving the continuous improvement of performance expectations for innovative drugs and industry chain.
The commercialization period of innovative drugs in the industry chain, driven purely by incremental value, is entering the phase of realization. The scarce incremental prosperity of the pharmaceutical sector continues to rise, with increasing international competitiveness, and there is still room for upward valuation.
Pharmaron Beijing Posts 13% Fall in Q3 Profit
Kanglong Chemical: Report for the third quarter of 2024
No Data
No Data
102884128 : getting disappointed with this counter. every day drop.